A
Arlene Chan
Researcher at The Breast Cancer Research Foundation
Publications - 127
Citations - 11087
Arlene Chan is an academic researcher from The Breast Cancer Research Foundation. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 29, co-authored 108 publications receiving 9675 citations. Previous affiliations of Arlene Chan include Curtin University & Hollywood Private Hospital.
Papers
More filters
Journal ArticleDOI
Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer
Charles E. Geyer,John K. Forster,Deborah Lindquist,Stephen Chan,C. Gilles Romieu,Tadeusz Pienkowski,Agnieszka Jagiełło-Gruszfeld,John Crown,Arlene Chan,Bella Kaufman,Dimosthenis Skarlos,Mario Campone,Neville Davidson,Mark S. Berger,Cristina Oliva,Stephen D. Rubin,S. Stein,David Cameron +17 more
TL;DR: Lapatinib plus capecitabine is superior to cape citabine alone in women with HER2-positive advanced breast cancer that has progressed after treatment with regimens that included an anthracycline, a taxane, and trastuzumab.
Journal ArticleDOI
Adjuvant trastuzumab in HER2-positive breast cancer.
Dennis J. Slamon,Wolfgang Eiermann,Nicholas J. Robert,Tadeusz Pienkowski,Miguel Martin,Michael F. Press,John R. Mackey,John A. Glaspy,Arlene Chan,M. Pawlicki,Tamás Pintér,Vicente Valero,Mei Ching Liu,Guido Sauter,Gunter von Minckwitz,Frances M. Visco,Valerie Bee,Marc Buyse,Belguendouz Bendahmane,Isabelle Tabah-Fisch,Mary Ann Lindsay,Alessandro Riva,John Crown +22 more
TL;DR: The addition of 1 year of adjuvant trastuzumab significantly improved disease-free and overall survival among women with HER2-positive breast cancer and the risk-benefit ratio favored the nonanthracycline TCH regimen over AC-T plus trastzumab, given its similar efficacy, fewer acute toxic effects, and lower risks of cardiotoxicity and leukemia.
Journal ArticleDOI
Phase III Study of Bevacizumab Plus Docetaxel Compared With Placebo Plus Docetaxel for the First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer
David Miles,Arlene Chan,Luc Dirix,Javier Cortes,Xavier Pivot,Piotr Tomczak,Thierry Delozier,Joohyuk Sohn,Louise Provencher,Fabio Puglisi,Nadia Harbeck,Guenther G. Steger,Andreas Schneeweiss,Andrew M Wardley,Andreas Chlistalla,Gilles Romieu +15 more
TL;DR: Bvacizumab 15 mg/kg every 3 weeks significantly increased PFS when combined with docetaxel as first-line therapy for MBC compared with docentaxel plus placebo and had limited impact on the known toxicity profile of docetAXel.
Journal ArticleDOI
A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses
David Cameron,Michelle Casey,Michael F. Press,Deborah Lindquist,Tadeusz Pienkowski,C. Gilles Romieu,Stephen Chan,Agnieszka Jagiełło-Gruszfeld,Bella Kaufman,John Crown,Arlene Chan,Mario Campone,Patrice Viens,Neville Davidson,Veira Gorbounova,Johannes Isaac Raats,Dimosthenis Skarlos,B. Newstat,Debasish F. Roychowdhury,Paolo Paoletti,Cristina Oliva,Stephen D. Rubin,S. Stein,Charles E. Geyer +23 more
TL;DR: The addition of lapatinib to capecitabine provides superior efficacy for women with HER2-positive, advanced breast cancer progressing after treatment with anthracycline-, taxane-, and trastuzumab-based therapy.
Proceedings ArticleDOI
Phase III Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Docetaxel (AC→T) with Doxorubicin and Cyclophosphamide Followed by Docetaxel and Trastuzumab (AC→TH) with Docetaxel, Carboplatin and Trastuzumab (TCH) in Her2neu Positive Early Breast Cancer Patients: BCIRG 006 Study.
DJ Slamon,Wolfgang Eiermann,Nicholas J. Robert,Tadeusz Pienkowski,Miguel Martín,J. Rolski,Arlene Chan,John R. Mackey,MC Liu,Tamás Pintér,V. Valero,Carla I. Falkson,Tommy Fornander,TA Shiftan,S. Olsen,Marc Buyse,T. Kiskartalyi,V. Landreau,V. Wilson,Michael F. Press,John Crown +20 more
TL;DR: The results of this trial help define the role of trastuzumab in the breast cancer HER2-positive adjuvant setting, as well as the risks/benefits of adjUvant trastzumab within the context of overall safety including cardiac toxicity.